Brief: IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation For Darovasertib Monotherapy In Neoadjuvant Uveal Melanoma
31/03/2025 11:03
March 31 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES RECEIVES US FDA BREAKTHROUGH THERAPY DESIGNATION FOR DAROVASERTIB MONOTHERAPY IN NEOADJUVANT UVEAL MELANOMA IDEAYA BIOSCIENCES INC: TARGETING TO INITIATE A PH3 REGISTRATIONAL STUDY IN NEOADJUVANT UM IN H1 2025 Source text: ID:nPnH40BTa Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj